Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms. A research team assessed the impact of GLP-1 receptor agonist in weight loss through genetic studies, aiming to understand whether the use of these medications reduces weight due to muscle or fat mass loss. This genetic study revealed that GLP-1 receptor agonists reduce weight by reducing more fat mass than muscle mass.